Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Quest DiagnosticsDGX -0.39%80 FCF Margin % is 5.66% as of Mar. 2026, which is 52% below its 10-year median of 11.87. GuruFocus rates DGX with a GF Score™ of 80/100 and a GF Value™ of $188.42 (Fairly Valued). The stock has 8 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Quest Diagnostics ranks better than 77.83% on this metric.
The historical rank and industry rank for Quest Diagnostics's FCF Margin % or its related term are showing as below:
DGX'
s FCF Margin % Range Over the Past 10 Years
Min: 9.21 Med: 11.87 Max: 16.96
Current: 11.76
During the past 13 years, the highest FCF Margin % of Quest Diagnostics was 16.96%. The lowest was 9.21%. And the median was 11.87%.
DGX's FCF Margin % is ranked better than 77.83% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.8
vs DGX: 11.76
Quest Diagnostics FCF Margin % Related Terms
Quest Diagnostics FCF Margin % Historical Data
* Premium members only.
The historical data trend for Quest Diagnostics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Quest Diagnostics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quest Diagnostics FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Quest Diagnostics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Quest Diagnostics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quest Diagnostics (DGX) has a FCF Margin % of 5.66% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Quest Diagnostics and its competitors. This is 52% below median its historical median of 11.87. Over the past decade, Quest Diagnostics' FCF Margin % has ranged from 9.21 to 16.96. According to the industry distribution chart, Quest Diagnostics ranks #45 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 22.2%.
Is Quest Diagnostics' FCF Margin % too high?
Quest Diagnostics' current FCF Margin % of 5.66% is 52% below median its 10-year median of 11.87. Over the past 10 years, this metric has ranged from a low of 9.21 to a high of 16.96. Based on the distribution chart, Quest Diagnostics ranks #45 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Quest Diagnostics has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Quest Diagnostics' FCF Margin % compare to LH and MTD?
According to the Medical Diagnostics & Research industry distribution chart, Quest Diagnostics ranks #45 out of 203 companies for FCF Margin %. This places Quest Diagnostics in the top 22% of its industry — outperforming the majority of peers. Historically, Quest Diagnostics' own FCF Margin % has ranged from 9.21 to 16.96 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Quest Diagnostics and its competitors. Quest Diagnostics's current FCF Margin % is 5.66%, which is 52% below median its own 10-year median of 11.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Quest Diagnostics (DGX) is currently considered Fairly Valued. The stock's GF Value™ is $188.42, compared to a current price of $206.84 — trading 9.8% above its estimated fair value. The current FCF Margin % is 5.66%, which is 52% below median its 10-year median of 11.87. Quest Diagnostics' overall GF Score™ is 80/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Quest Diagnostics (DGX), the current FCF Margin % is 5.66% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Quest Diagnostics (DGX) Overvalued in 2026?
Based on GuruFocus' analysis, Quest Diagnostics stock appears to be overvalued.
The current stock price of $206.84 is trading 9.8% above its estimated GF Value™ of $188.42.
GuruFocus considers Quest Diagnostics to be Fairly Valued.
Key valuation signals for DGX:
FCF Margin %: 5.66% (52% below median its 10-year median of 11.87)
GF Value™: $188.42 vs. price of $206.84 (9.8% above fair value)
No single metric tells the full story. See the DGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
80GF Score
Get the complete analysis for DGX
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DGX has been successfully added to your 
